Press Releases Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 15/07/2025 am IST			5-day change	1st Jan Change
135.13 ^USD	+1.25%		+5.67%	-1.00%

15/07	Neurocrine Biosciences, Inc. Presents One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting	CI
14/07	Neurocrine Biosciences, Inc. Presents One-Year Data Showing Sustained Efficacy of CRENESSITY in Adult Patients, at ENDO 2025	CI

Press Releases

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting	15/07	PR
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025	14/07	PR
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results	10/07	PR
Neurocrine Biosciences : 2025 Corporate Responsibility Report	08/07	PU
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist	01/07	PR
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea	27/06	PR
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer	10/06	PR
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia	02/06	PR
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting	19/05	AQ
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting	16/05	PR
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia	16/05	PR
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia	15/05	PR
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups	08/05	PR
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May	07/05	PR
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia	06/05	PR
Neurocrine: Q1 Earnings Snapshot	06/05	AQ
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance	06/05	PR
Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia	02/05	AQ
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia	30/04	PR
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA Capsules in Older Adults with Tardive Dyskinesia in the Journal of Clinical Psychiatry	25/04	AQ
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry	25/04	PR
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results	15/04	PR
Neurocrine Biosciences : 2024 Annual Report*	10/04	PU
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer	07/04	AQ
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer	04/04	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Pharmaceuticals

Press Releases

Filters